For patients with driver gene-positive NSCLC (such as EGFR, ALK, or ROS1 mutations), targeted therapies, including EGFR inhibitors or ALK inhibitors, are the standard of care. This evidence concerns the gene ALK and non-small cell lung carcinoma.